

1 September 2025

**Our Ref:** FOI 1325

Dear

**Freedom of Information Act 2000  
Information in Relation to Atopic Dermatitis Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 4 August 2025.

A response to the questions you have raised has been provided by the Surgery, Elective Care, Maternity and Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Olivia Robinson**  
**Information Governance Officer**

**Q1. How many patients were treated in the last 4 months (April to July 2025) by the dermatology department with each of the following products:**

- **Abrocitinib**
- **Baricitinib**
- **Dupilumab**
- **Lebrikizumab**
- **Tralokinumab**
- **Upadacitinib**
- **Nemolizumab**

A1. Please see Table 1 below for a breakdown of how many patients were treated in the last 4 months (April to July 2025) by the dermatology department with the listed products.

Table 1

<b>Medication</b>	<b>Number of Patients Treated From April to July 2025</b>
Abrocitinib	Nil
Baricitinib	2
Dupilumab	137
Lebrikizumab	5
Tralokinumab	1
Upadacitinib	20
Nemolizumab	Nil

**Q2. In the last 4 months, how many new patients have been initiated on the following treatments by the dermatology department. Patients are considered initiated on a treatment if they have not been treated with the named treatment in the previous 8 months.**

- **Abrocitinib – 0**
- **Baricitinib – 0**
- **Dupilumab – 16**
- **Lebrikizumab – 2**
- **Tralokinumab – 1**
- **Upadacitinib – 5**
- **Nemolizumab - 0**

A2. Please see Table 2 below for a breakdown of how many new patients have been initiated on the listed treatments by the dermatology department.

Table 2

<b>Medication</b>	<b>Number of Patients Treated From April to July 2025</b>
Abrocitinib	Nil
Baricitinib	Nil
Dupilumab	16
Lebrikizumab	2
Tralokinumab	1
Upadacitinib	5
Nemolizumab	Nil